Bio-ARROW - SmartForm - NIH Guidelines
Please select the citation(s) applicable to your research. If you are having trouble identifying which boxes to check for your research activities, please call our office to speak to a protocol advisor at 608-263-2037.
- Risk Group 1 Organisms
- Risk Group 2 or Risk Group 3 Organisms
- Viruses
- Risk Group 4 Organisms
- 10L Cultures
- Recombinant Tissue Culture
- Human Gene Transfer
- Transgenic Rodents at BSL-1
- Transgenic Rodents at BSL-2 or BSL3
- Recombinant Microbes or Cells and Rodents
- Transgenic Animals Other Than Rodents
- Transgenic Arthropods
- Transgenic Plants
- Plants Associated with Transgenic Microbes/Arthropods/Small Animals
- Biological Toxins
Expression of Risk Group 1 or Risk Group 2 nucleic acids in E. coli K12, S. cerevisiae, S. uvarum, K. lactis, B. subtilis, B. licheniformis – III-F
Non-K12 E. coli strains (such as BL21) – III-E
All other RG1 organisms – III-E
Risk Group 2 or Risk Group 3 Organisms
Recombinant or synthetic nucleic acid molecules into RG2 or RG3 microbes – III-D
DNA from Risk Group 3 microbes cloned into E. coli K12, S cerevisiae, K lactis, B. subtilis and B. licheniformis - III-D
DNA from RG2 or RG3 microbes cloned into nonpathogenic prokaryotic or lower eukaryotic host-vector systems other than E. coli K12, S. cerevisiae, K. lactis, B. subtilis and B. licheniformis – III-D
Deliberate transfer of drug resistance trait to microorganism that are not known to acquire the trait naturally if the trait could compromise the use of drugs to control disease agents in humans, animals, or plants – III-A
Use of infectious or defective viruses in the presence of a helper system – III-D
Use of transgenic influenza viruses – III-D
DNA from RG4 microbes cloned into E. coli K12, S. cerevisiae, K. lactis, B. subtilis and B. licheniformis - III-D
DNA from RG4 microbes cloned into nonpathogenic prokaryotic or lower eukaryotic host-vector systems other than E. coli K12, S. cerevisiae, K. lactis, B. subtilis and B. licheniformis if demonstration that only a fraction of genome is present in recombinant organism – III-D
10L cultures of microbes – III-D
Cells containing less than two-thirds of any eukaryotic viral genome – III-E
Cells containing less than one-half of any eukaryotic viral genome – III-F
Infectious or defective RG2 or RG3 virus + helper virus in tissue culture – III-D
Recombinant or synthetic nucleic acid molecules introduced into humans – III-C
Synthetic nucleic acid molecules, or DNA or RNA derived from synthetic nucleic acid molecules, possessing biological properties that enable introduction of stable genetic modifications into the genome – III-C
Creation of transgenic rodents at BSL-1 – III-E
Purchase and/or maintenance of transgenic rodents at BSL-1 – III-F
Breeding rodents using two different BSL-1 transgenic strains if the parental rodent contains the following genetic modifications: (i) incorporation of more than one-half of the genome of an exogenous eukaryotic virus from a single family of viruses; or (ii) incorporation of a transgene that is under the control of a gammaretroviral long terminal repeat (LTR); or the rodent that results from the breeding contains more than one-half of an exogenous viral genome from a single family of viruses – III-E
Breeding rodents using two different BSL-1 transgenic strains that do not have the genetic modifications listed above – III-F
Breeding rodents from one BSL-1 transgenic strain – III-F
Experiments involving the generation or use of gene drive modified rodents – III-D
Transgenic Rodents at BSL-2 or BSL-3
Creation of transgenic rodents at BSL-2 or BSL-3 – III-D
Breeding transgenic rodents for one strain at BSL-2 or BSL-3 – III-D
Experiments involving the generation or use of gene drive modified animals – III-D
Recombinant Microbes or Cells and Rodents
RG1, RG2, RG3 microbes in rodents – III-D
Viral vectors in rodents – III-D
Recombinant cells in rodents – III-D
Transgenic Animals Other Than Rodents
Creation, breeding, purchasing, or transferring transgenic animals – III-D
RG1, RG2, RG3 microbes in animals – III-D
Viral vectors in animals – III-D
Recombinant cells in animals – III-D
Experiments involving the generation or use of gene drive modified animals – III-D
Breeding of recombinant or synthetic nucleic acid molecule modified arthropods – III-D
Creation of recombinant or synthetic nucleic acid molecule modified arthropods – III-D
Purchase of recombinant or synthetic nucleic acid molecule modified arthropods – III-D
Experiments with recombinant or synthetic nucleic acid molecule modified arthropods associated with plants at BSL-1 or BSL-2 – III-E
Experiments involving the generation or use of gene drive modified arthropods– III-D
Transgenic plants that are noxious weeds or can interbreed with noxious weeds – III-E
Introduction of DNA that represents the complete genome of a non-exotic infectious agent into plants – III-E
Transgenic exotic/detrimental plant species with the potential for serious detrimental effects – III-D
Experiments involving the generation or use of gene drive modified plants – III-D
Plants Associated with Transgenic Microbes/Arthropods/Small Animals
Recombinant or synthetic nucleic acid molecule modified non-exotic microbes with the potential for serious detrimental impact on plants associated with plants – III-E
Recombinant or synthetic nucleic acid molecule modified exotic microorganisms, arthropods, or small animals with no potential for serious detrimental impact on plants – III-E
Recombinant or synthetic nucleic acid molecule modified microbes that are exotic or have the potential for serious detrimental impact on plants – III-D
Deliberate transfer of drug resistance trait to microorganism that are not known to acquire the trait naturally if the trait could compromise the use of drugs to control disease agents in humans, animals, or plants – III-A
Formation of recombinant or synthetic toxin molecules with LD50 less than 100ng/kg body weight – III-B
Still have questions? Call the Office of Biological Safety (OBS) at 608-263-2037. We are happy to help.